Literature DB >> 24824313

Insulin-like growth factor pathway genetic polymorphisms, circulating IGF1 and IGFBP3, and prostate cancer survival.

Yin Cao, Sara Lindström, Fredrick Schumacher, Victoria L Stevens, Demetrius Albanes, Sonja Berndt, Heiner Boeing, H Bas Bueno-de-Mesquita, Federico Canzian, Saioa Chamosa, Stephen J Chanock, W Ryan Diver, Susan M Gapstur, J Michael Gaziano, Edward L Giovannucci, Christopher A Haiman, Brian Henderson, Mattias Johansson, Loïc Le Marchand, Domenico Palli, Bernard Rosner, Afshan Siddiq, Meir Stampfer, Daniel O Stram, Rulla Tamimi, Ruth C Travis, Dimitrios Trichopoulos, Walter C Willett, Meredith Yeager, Peter Kraft, Ann W Hsing, Michael Pollak, Xihong Lin, Jing Ma.   

Abstract

BACKGROUND: The insulin-like growth factor (IGF) signaling pathway has been implicated in prostate cancer (PCa) initiation, but its role in progression remains unknown.
METHODS: Among 5887 PCa patients (704 PCa deaths) of European ancestry from seven cohorts in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium, we conducted Cox kernel machine pathway analysis to evaluate whether 530 tagging single nucleotide polymorphisms (SNPs) in 26 IGF pathway-related genes were collectively associated with PCa mortality. We also conducted SNP-specific analysis using stratified Cox models adjusting for multiple testing. In 2424 patients (313 PCa deaths), we evaluated the association of prediagnostic circulating IGF1 and IGFBP3 levels and PCa mortality. All statistical tests were two-sided.
RESULTS: The IGF signaling pathway was associated with PCa mortality (P = .03), and IGF2-AS and SSTR2 were the main contributors (both P = .04). In SNP-specific analysis, 36 SNPs were associated with PCa mortality with P trend less than .05, but only three SNPs in the IGF2-AS remained statistically significant after gene-based corrections. Two were in linkage disequilibrium (r 2 = 1 for rs1004446 and rs3741211), whereas the third, rs4366464, was independent (r 2 = 0.03). The hazard ratios (HRs) per each additional risk allele were 1.19 (95% confidence interval [CI] = 1.06 to 1.34; P trend = .003) for rs3741211 and 1.44 (95% CI = 1.20 to 1.73; P trend < .001) for rs4366464. rs4366464 remained statistically significant after correction for all SNPs (P trend.corr = .04). Prediagnostic IGF1 (HRhighest vs lowest quartile = 0.71; 95% CI = 0.48 to 1.04) and IGFBP3 (HR = 0.93; 95% CI = 0.65 to 1.34) levels were not associated with PCa mortality.
CONCLUSIONS: The IGF signaling pathway, primarily IGF2-AS and SSTR2 genes, may be important in PCa survival.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24824313      PMCID: PMC4081624          DOI: 10.1093/jnci/dju085

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  32 in total

1.  A multiple testing correction method for genetic association studies using correlated single nucleotide polymorphisms.

Authors:  Xiaoyi Gao; Joshua Starmer; Eden R Martin
Journal:  Genet Epidemiol       Date:  2008-05       Impact factor: 2.135

2.  Expression and imprinting status of human PEG8/IGF2AS, a paternally expressed antisense transcript from the IGF2 locus, in Wilms' tumors.

Authors:  T Okutsu; Y Kuroiwa; F Kagitani; M Kai; K Aisaka; O Tsutsumi; Y Kaneko; K Yokomori; M A Surani; T Kohda; T Kaneko-Ishino; F Ishino
Journal:  J Biochem       Date:  2000-03       Impact factor: 3.387

3.  High expression of somatostatin receptors and messenger ribonucleic acid for its receptor subtypes in organ-confined and locally advanced human prostate cancers.

Authors:  G Halmos; A V Schally; B Sun; R Davis; D G Bostwick; A Plonowski
Journal:  J Clin Endocrinol Metab       Date:  2000-07       Impact factor: 5.958

Review 4.  Circulating insulin-like growth factor peptides and prostate cancer risk: a systematic review and meta-analysis.

Authors:  Mari-Anne Rowlands; David Gunnell; Ross Harris; Lars J Vatten; Jeff M P Holly; Richard M Martin
Journal:  Int J Cancer       Date:  2009-05-15       Impact factor: 7.396

Review 5.  Resistance pathways relevant to insulin-like growth factor-1 receptor-targeted therapy.

Authors:  Andrea Wahner Hendrickson; Paul Haluska
Journal:  Curr Opin Investig Drugs       Date:  2009-10

Review 6.  Genotype imputation.

Authors:  Yun Li; Cristen Willer; Serena Sanna; Gonçalo Abecasis
Journal:  Annu Rev Genomics Hum Genet       Date:  2009       Impact factor: 8.929

7.  Genetic and plasma variation of insulin-like growth factor binding proteins in relation to prostate cancer incidence and survival.

Authors:  Mattias Johansson; James D McKay; Sabina Rinaldi; Fredrik Wiklund; Hans-Olov Adami; Henrik Grönberg; Rudolf Kaaks; Pär Stattin
Journal:  Prostate       Date:  2009-09-01       Impact factor: 4.104

8.  IGF-1 and IGFBP-3: Risk of prostate cancer among men in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.

Authors:  Jocelyn M Weiss; Wen-Yi Huang; Sabina Rinaldi; Thomas R Fears; Nilanjan Chatterjee; David Chia; E David Crawford; Rudolf Kaaks; Richard B Hayes
Journal:  Int J Cancer       Date:  2007-11-15       Impact factor: 7.396

Review 9.  Insulin and insulin-like growth factor signalling in neoplasia.

Authors:  Michael Pollak
Journal:  Nat Rev Cancer       Date:  2008-12       Impact factor: 60.716

10.  Serum insulin-like growth factor (IGF)-I and IGF-binding protein-3 concentrations and prostate cancer risk: results from the European Prospective Investigation into Cancer and Nutrition.

Authors:  Naomi E Allen; Timothy J Key; Paul N Appleby; Ruth C Travis; Andrew W Roddam; Sabina Rinaldi; Lars Egevad; Sabine Rohrmann; Jakob Linseisen; Tobias Pischon; Heiner Boeing; Nina Føns Johnsen; Anne Tjønneland; Henning Grønbaek; Kim Overvad; Lambartus Kiemeney; H Bas Bueno-de-Mesquita; Sheila Bingham; Kay Tee Khaw; Rosario Tumino; Franco Berrino; Amalia Mattiello; Carlotta Sacerdote; Domenico Palli; José Ramón Quirós; Eva Ardanaz; Carmen Navarro; Nerea Larrañaga; Carlos Gonzalez; Maria-José Sanchez; Antonia Trichopoulou; Cryssoula Travezea; Dimitrios Trichopoulos; Mazda Jenab; Pietro Ferrari; Elio Riboli; Rudolf Kaaks
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2007-06       Impact factor: 4.254

View more
  25 in total

Review 1.  Biomarkers in bile-complementing advanced endoscopic imaging in the diagnosis of indeterminate biliary strictures.

Authors:  Vennisvasanth Lourdusamy; Benjamin Tharian; Udayakumar Navaneethan
Journal:  World J Gastrointest Endosc       Date:  2015-04-16

Review 2.  Impact of Candidate Genetic Polymorphisms in Prostate Cancer: An Overview.

Authors:  S Salvi; V Conteduca; G Gurioli; D Calistri; V Casadio; U De Giorgi
Journal:  Mol Diagn Ther       Date:  2016-02       Impact factor: 4.074

3.  Metabolic syndrome, dyslipidemia and prostate cancer recurrence after primary surgery or radiation in a veterans cohort.

Authors:  L C Macleod; L J Chery; E Y C Hu; S B Zeliadt; S K Holt; D W Lin; M P Porter; J L Gore; J L Wright
Journal:  Prostate Cancer Prostatic Dis       Date:  2015-03-31       Impact factor: 5.554

Review 4.  IGF1 receptor and thyroid-associated ophthalmopathy.

Authors:  Michelle Mohyi; Terry J Smith
Journal:  J Mol Endocrinol       Date:  2017-12-22       Impact factor: 5.098

5.  Prediagnostic plasma IGFBP-1, IGF-1 and risk of prostate cancer.

Authors:  Yin Cao; Katharina Nimptsch; Irene M Shui; Elizabeth A Platz; Kana Wu; Michael N Pollak; Stacey A Kenfield; Meir J Stampfer; Edward L Giovannucci
Journal:  Int J Cancer       Date:  2014-11-10       Impact factor: 7.396

6.  Pre-diagnostic Serum Metabolomic Profiling of Prostate Cancer Survival.

Authors:  Jiaqi Huang; Stephanie J Weinstein; Steven C Moore; Andriy Derkach; Xing Hua; Alison M Mondul; Joshua N Sampson; Demetrius Albanes
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2019-05-16       Impact factor: 6.053

7.  Weight change, obesity and risk of prostate cancer progression among men with clinically localized prostate cancer.

Authors:  Barbra A Dickerman; Thomas U Ahearn; Edward Giovannucci; Meir J Stampfer; Paul L Nguyen; Lorelei A Mucci; Kathryn M Wilson
Journal:  Int J Cancer       Date:  2017-06-08       Impact factor: 7.396

8.  Expression of IGF/insulin receptor in prostate cancer tissue and progression to lethal disease.

Authors:  Thomas U Ahearn; Sam Peisch; Andreas Pettersson; Ericka M Ebot; Cindy Ke Zhou; Rebecca E Graff; Jennifer A Sinnott; Ladan Fazli; Gregory L Judson; Tarek A Bismar; Jennifer R Rider; Travis Gerke; June M Chan; Michelangelo Fiorentino; Richard Flavin; Howard D Sesso; Stephen Finn; Edward L Giovannucci; Martin Gleave; Massimo Loda; Zhe Li; Michael Pollak; Lorelei A Mucci
Journal:  Carcinogenesis       Date:  2018-12-31       Impact factor: 4.944

9.  Multivariate piecewise exponential survival modeling.

Authors:  Yan Li; Orestis A Panagiotou; Amanda Black; Dandan Liao; Sholom Wacholder
Journal:  Biometrics       Date:  2015-11-19       Impact factor: 2.571

10.  Association of insulin-like growth factor-binding protein-3 with radiotherapy response and prognosis of esophageal squamous cell carcinoma.

Authors:  Li-Ling Luo; Lei Zhao; Mian Xi; Li-Ru He; Jing-Xian Shen; Qiao-Qiao Li; Shi-Liang Liu; Peng Zhang; Dan Xie; Meng-Zhong Liu
Journal:  Chin J Cancer       Date:  2015-09-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.